The APOE ε4 genotype modulates CSF YKL‐40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Introduction: Among other metabolic functions, the apolipoprotein E (APOE) plays a crucial role in neuroinflammation. We aimed at assessing whether APOE ε4 modulates levels of glial cerebrospinal fluid (CSF) biomarkers and their structural cerebral correlates along the continuum of Alzheimer's disease (AD). Methods: Brain magnetic resonance imaging (MRI) scans were acquired in 110 participants (49 control; 19 preclinical; 27 mild cognitive impairment [MCI] due to AD; 15 mild AD dementia) and CSF concentrations of YKL‐40 and sTREM2 were determined. Differences in CSF biomarker concentrations and interactions in their association with gray‐matter volume according to APOE ε4 status were sought after. Results: Preclinical and MCI carriers showed higher YKL‐40 levels. There was a significant interaction in the association between YKL‐40 levels and gray‐matter volume according to ε4 status. No similar effects could be detected for sTREM2 levels. Discussion: Our findings are indicative of an increased astroglial activation in APOE ε4 carriers while both groups displayed similar levels of CSF AD core biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“Carriers of at least one ε4 allele (APOE ε4) are 3–4 times more likely to develop AD than noncarriers [5] and show significant atrophy especially in regions susceptible to AD-related atrophy such as the hippocampus [6–8].”
BackgroundAdvancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“Heterozygous missense mutations have been recently described to significantly increase the risk of Alzheimer’s disease, as well as other neurodegenerative diseases, with an odds ratio similar to that of carrying an APOE ε4 allele [27,28].”
BackgroundJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · cited 2×
“MCI due to AD patients (N5 27) were defined according to the National Institute on Aging -Alzheimer’s Association criteria [42].”
MethodThe role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 1×
“In the central nervous system, the ApoE protein is synthesized and secreted mainly by astrocytes [9], and to a lesser extent by microglia [10].”
BackgroundTakahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124
Adult mouse astrocytes degrade amyloid-β in vitro and in situ
Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, S. C., & Husemann, J. (2003) · Nature Medicine · doi:10.1038/nm838 · Cited by 909
Apolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857 · cited 2×
“In addition to its role for lipid metabolism, APOE has an important role in Ab aggregation and degradation [4,13] which may be mediated by glial cells: the ApoE has been described to promote the localization and degradation of Ab deposits by astrocytes [14] and bind to apoptotic neurons to promote phagocytosis by the…”
BackgroundTREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 1×
“The TREM2 receptor undergoes proteolytic processing, releasing its ectodomain into the extracellular space as a soluble variant (sTREM2) via shedding by a disintegrin andmetalloproteinase (ADAM) proteases and can be detected in human plasma and CSF [30,31].”
BackgroundSelf-citationApolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)
Atagi, Y., Liu, C.-C., Painter, M. M., Chen, X.-F., Verbeeck, C., Zheng, H., Li, X., Rademakers, R., Kang, S. S., Xu, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679043 · Cited by 587 · cited 7×
“The APOE gene has three major alleles (ε2, ε3, and ε4) which code for different isoforms of the ApoE.”
BackgroundInfluential
Cited by
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Self-citationTREM2 in Neurodegenerative Diseases
Jay, T. R., von Saucken, V. E., & Landreth, G. E. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0197-5 · Cited by 427
YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
Llorens, F., Thüne, K., Tahir, W., Kanata, E., Diaz-Lucena, D., Xanthopoulos, K., Kovatsi, E., Pleschka, C., Garcia-Esparcia, P., Schmitz, M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0226-4 · Cited by 249
Self-citationSignificance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer
Yu, J. E., Yeo, I. J., Han, S.-B., Yun, J., Kim, B., Yong, Y. J., Lim, Y.-S., Kim, T. H., Son, D. J., & Hong, J. T. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01131-9 · Cited by 109
Metadata
- Authors
- Gispert, J. D., Monté, G. C., Suárez‐Calvet, M., Falcon, C., Tucholka, A., Rojas, S., Rami, L., Sánchez‐Valle, R., Lladó, A., Kleinberger, G., Haass, C., & Molinuevo, J. L.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2016-12-22
- Volume
- 6
- Issue
- 1
- Pages
- 50-59
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W2563207743
- Cited by
- 52
- References
- 24
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The APOE ε4 genotype modulates CSF YKL‐40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. https://app.cochat.ai/papers/10.1016/j.dadm.2016.12.002
- The paper
- Gispert, J. D., Monté, G. C., Suárez‐Calvet, M., Falcon, C., Tucholka, A., Rojas, S., Rami, L., Sánchez‐Valle, R., Lladó, A., Kleinberger, G., Haass, C., & Molinuevo, J. L. (2017). The APOE ε4 genotype modulates CSF YKL‐40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. https://doi.org/10.1016/j.dadm.2016.12.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.